Merck Logs Fourth Straight Beat on KEYTRUDA Growth, Secures Terns Acquisition
Merck delivered its fourth consecutive quarterly earnings beat, powered by continued KEYTRUDA growth and strength across its oncology pipeline, yet shares declined on profit-taking. The company also completed its acquisition of Terns Pharmaceuticals, securing rights to the MK-0482 small-molecule checkpoint inhibitor to bolster its immuno-oncology portfolio.
1. Earnings Performance and KEYTRUDA Growth
Merck reported its fourth consecutive quarterly earnings beat, with KEYTRUDA once again leading growth in its oncology portfolio. Despite the strong performance, shares dipped modestly as investors weighed short-term profit-taking against the company’s long-term pipeline outlook.
2. Acquisition of Terns Pharmaceuticals
Merck finalized the acquisition of Terns Pharmaceuticals, gaining rights to the MK-0482 small-molecule checkpoint inhibitor program. This strategic move is aimed at expanding Merck’s immuno-oncology pipeline ahead of several key patent expirations later this decade.